The use of cannabinoids in multiple sclerosis

Lara Teare, John Zajicek

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Naturally occurring cannabinoids including Delta9-tetrahydrocannabinol and cannabidiol as well as endocannabinoids and synthetic cannabinoids may have a role in modulating experimental models of multiple sclerosis. Recent clinical studies to treat symptoms of multiple sclerosis have shown varying results, which may reflect issues relating to the way in which such studies were conducted. There is now increasing interest in the potential role of cannabinoids not only in symptom relief, but also for their possible neuroprotective actions.

Original languageEnglish
Pages (from-to)859-69
Number of pages11
JournalExpert Opinion on Investigational Drugs
Issue number7
Publication statusPublished - Jul 2005


  • Animals
  • Cannabinoid Receptor Modulators
  • Cannabinoids
  • Humans
  • Multiple Sclerosis
  • Neuroprotective Agents
  • Pain
  • Receptors, Cannabinoid


Dive into the research topics of 'The use of cannabinoids in multiple sclerosis'. Together they form a unique fingerprint.

Cite this